This product is contraindicated in an individual with a history of hypersensitivity to any of its ingredients
Serious Risks Rare but serious risks may include: Pancreatitis Gallbladder problems Thyroid tumor warnings Severe digestive issues Patients should always discuss risks with a licensed healthcare provider
Mechanism of Action GLP-1 agonists exert their effects through multiple mechanisms, all of which contribute to their therapeutic benefits
There is more direct animal experimental evidence on the effect of GLP-1RAs on HCC than on fibrosis
The same study found that people taking Wegovy were more likely than those in the placebo group to lose 5, 10, 15, or 20% of their starting weight
Unfortunately, this program is not for everyone because of the very high drug costs involved and because medical insurance plans rarely cover these costs, but for patients able to afford them, GLP-1 drugs may be somewhat more effective than traditional weight loss drugs